Monoclonal antibodies disappoint in early Parkinson's disease
Two monoclonal antibodies targeting aggregated α-synuclein have failed to improve clinical or imaging measures of early-stage Parkinson’s disease
Stay updated with breaking news from Alan Whone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two monoclonal antibodies targeting aggregated α-synuclein have failed to improve clinical or imaging measures of early-stage Parkinson’s disease
Failure of two agents in two phase II trials could spell the end for one avenue of treatment
Diagnosed with the condition in 2019, former BBC tech correspondent Rory Cellan-Jones is on a mission to find out how science can treat it
In a world first, UK doctors have implanted a device into a brain to reverse the symptoms of Parkinson's disease.
Surgeons at Southmead Hospital in Bristol, England, are implementing a tiny deep brain stimulation (DBS) device into the skull.